Dr Reddy's Lab gains after relaunching a generic in US

Image
Capital Market
Last Updated : Dec 31 2015 | 12:01 AM IST

Dr Reddy's Laboratories rose 1.33% to Rs 3,143.50 at 14:06 IST on BSE after the company announced the relaunch of its Esomeprazole Magnesium Delayed-Release Capsules in the US market.

The company made the announcement during market hours today, 30 December 2015.

Meanwhile, the S&P BSE Sensex was down 11.79 points or 0.05% at 26,067.69.

On BSE, so far 39,000 shares were traded in the counter as against average daily volume of 69,414 shares in the past one quarter.

The stock was volatile. The stock rose as much as 2.21% at the day's high of Rs 3,171 so far during the day. The stock rose 0.59% at the day's low of Rs 3,120.85 so far during the day. The stock had hit a record high of Rs 4,382.95 on 20 October 2015. The stock had hit a 52-week low of Rs 2,950.50 on 11 December 2015.

The stock had outperformed the market over the past one month till 29 December 2015, gaining 0.1% compared with Sensex's 0.19% fall. The scrip had, however, underperformed the market in past one quarter, sliding 23.87% as against Sensex's 1.17% rise.

The large-cap company has equity capital of Rs 85.30 crore. Face value per share is Rs 5.

Dr Reddy's Laboratories announced the relaunch of its Esomeprazole Magnesium Delayed-Release Capsules, a therapeutic equivalent generic version of Nexium Delayed Release capsules in the US market. Nexium is a registered trademark of Astrazeneca AB Corporation. The re-launch is due to a change in the capsule color.

Dr Reddy's Laboratories' consolidated net profit rose 25.7% to Rs 721.89 crore on 11.2% growth in net sales to Rs 3988.96 crore in Q2 September 2015 over Q2 September 2014.

Dr Reddy's Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 30 2015 | 2:15 PM IST

Next Story